抗ウイルス薬 - 世界市場の考察、競合情勢、市場予測（2030年）

世界の抗ウイルス薬の市場規模は、2030年までに514億6,621万米ドルに達し、2024年～2030年の予測期間にCAGRで3.65%の成長が見込まれます。市場は、世界中でHIV、肝炎、エボラ出血熱、その他のウイルス性疾患の有病率が増加しているため、大幅な市場成長を示しています。さらに、ウイルス性疾患に対する意識の高まりや、ウイルス性疾患に罹患しやすい老年人口の増加も、抗ウイルス薬の需要の増加に寄与しています。さらに、薬剤の有効性を向上させるための、キメラ機構を標的としたタンパク質分解、標的共有結合阻害剤機構などの抗ウイルス薬における進歩が、抗ウイルス薬市場に拍車をかけます。同様に、薬剤の承認や上市の急増に伴う研究開発活動の増加や、市場における主要企業のプレゼンスは、市場における抗ウイルス薬の必要性を生み出す主な要因です。したがって、市場は2024年～2030年の予測期間に大幅なCAGRで成長すると推定されます。

抗ウイルス薬の市場力学

世界保健機関（WHO）（2022）によると、2022年に世界で約3,840万人がHIVに感染しています。また、3,670万人近くが成人（15歳以上）であり、約170万人が15歳未満の小児であるとしています。

また、UNAIDSの2022年のレポートでは、2022年に世界で150万人近くが新たにHIVに感染したと付け加えています。上記の資料は2022年に世界で2,870万人が抗レトロウイルス療法を受けられるようになるとも言及しています。

さらに、Joint United Nations Programme on HIV and AIDSも、2020年6月現在、2,600万人が抗レトロウイルス療法を受け、2019年に約2,540万人が抗レトロウイルス療法を受けたと推定しています。このデータは、抗ウイルス治療薬へのアクセスが世界中で継続的に増加していることを示しており、このことが市場成長を推進する主な要因の1つとして作用しています。したがって、HIV感染症の有病率の増加と感染症に関する意識の高まりが、結果としてHIV感染症の治療に使用される抗ウイルス薬の需要を増加させます。

さらに、研究開発活動の活発化や、世界中で拡大する製品の上市と承認、パイプラインにある多数の薬剤のプレゼンス、抗ウイルス薬の製造と研究を拡大するための主要企業による戦略的活動は、抗ウイルス薬の市場を強化します。例えば、2022年4月、宿主を標的とした抗ウイルス療法の開発に特化したバイオ医薬品企業であるAtriva Therapeutics GmbHは、連邦政府から1,140万ユーロの資金提供を受けました。同社はこの資金を、現在RESPIREと呼ばれるフェーズII臨床試験にある薬剤、ATR-002の開発に充てる予定です。

また、Gilead Sciences, Inc.は2022年1月、米国食品医薬品局（FDA）より、入院または死亡を含む重症COVID-19への進行リスクが高い非入院成人と思春期患者の治療薬としてのVeklury®（レムデシビル）の追加新薬承認申請（sNDA）が迅速承認されたと発表しました。今回の承認により、COVID-19の入院患者に対する抗ウイルス標準治療薬であるVekluryの役割が拡大されることになります。

さらに、分子生物学の進歩は、ヌクレオシドとヌクレオチドアナログが第一選択抗ウイルス薬として使用されるようになるのと並行して、医薬品開発を促進しています。現在の開発パイプラインによれば、今後多くの低分子ベースの抗ウイルス薬が製品承認を取得すると予測され、予測期間に市場成長をかつてない高みに押し上げます。

したがって、2024年～2030年の予測期間に上記の要因が総合的に抗ウイルス薬市場全体を牽引します。

しかし、抗ウイルス薬耐性の出現や、抗ウイルス薬に伴う副作用、高い治療費、規制当局の厳しい承認プロセスなどが、抗ウイルス薬市場の成長にとっての課題となる可能性があります。

当レポートでは、世界の抗ウイルス薬市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 抗ウイルス薬市場レポートのイントロダクション

第2章 抗ウイルス薬市場のエグゼクティブサマリー

• 調査範囲
• 市場の概要
• 競合の評価

第3章 規制分析

第4章 抗ウイルス薬市場の主な要因の分析

• 抗ウイルス薬市場の促進要因
• 抗ウイルス薬市場の抑制要因と課題
• 抗ウイルス薬市場の機会

第5章 抗ウイルス薬市場のポーターのファイブフォース分析

第6章 抗ウイルス薬市場に対するCOVID-19の影響分析

第7章 抗ウイルス薬市場のレイアウト

• 薬剤クラス別
  • DNAポリメラーゼ阻害剤
  • 逆転写酵素阻害剤
  • ノイラミニダーゼ阻害剤
  • プロテアーゼ阻害剤
  • その他
• 適応症別
  • HIV感染症
  • ヘルペス
  • 肝炎
  • インフルエンザ
• 流通チャネル別
  • 病院薬局
  • 小売薬局
  • eコマース
• 地域
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 抗ウイルス薬市場の企業と製品のプロファイル

• AbbVie Inc.
• Bristol-Myers Squibb Company
• Gilead Sciences, Inc.
• F. Hoffmann-La Roche Ltd
• Pfizer Inc.
• Cipla Inc.
• Lupin.
• ENTOD INTERNATIONAL
• AstraZeneca
• Dr. Reddy's Laboratories Ltd.
• GSK plc.
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Sanofi
• ViiV Healthcare
• Aurobindo Pharma.
• Sun Pharmaceutical Industries Ltd.
• Viatris Inc.
• Boehringer Ingelheim

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項、お問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: COVID-19 Impact Analysis on Antiviral Drugs Market
• Table 3: Antiviral Drugs Market Analysis in Global (2021-2030)
• Table 4: Antiviral Drugs Market Analysis in Global by Drug Class (2021-2030)
• Table 5: Antiviral Drugs Market Analysis in Global by Indication (2021-2030)
• Table 6: Antiviral Drugs Market Analysis in Global by Distribution Channel (2021-2030)
• Table 7: Antiviral Drugs Market Analysis in Global by Geography (2021-2030)
• Table 8: Antiviral Drugs Market Analysis in North America (2021-2030)
• Table 9: Antiviral Drugs Market Analysis in North America by Country (2021-2030)
• Table 10: Antiviral Drugs Market Analysis in the US (2021-2030)
• Table 11: Antiviral Drugs Market Analysis in Canada (2021-2030)
• Table 12: Antiviral Drugs Market Analysis in Mexico (2021-2030)
• Table 13: Antiviral Drugs Market Analysis in Europe (2021-2030)
• Table 14: Antiviral Drugs Market Analysis in Europe by Country (2021-2030)
• Table 15: Antiviral Drugs Market Analysis in France (2021-2030)
• Table 16: Antiviral Drugs Market Analysis in Germany (2021-2030)
• Table 17: Antiviral Drugs Market Analysis in the UK (2021-2030)
• Table 18: Antiviral Drugs Market Analysis in Italy (2021-2030)
• Table 19: Antiviral Drugs Market Analysis in Spain (2021-2030)
• Table 20: Antiviral Drugs Market Analysis in the Rest of Europe (2021-2030)
• Table 21: Antiviral Drugs Market Analysis in Asia-Pacific (2021-2030)
• Table 22: Antiviral Drugs Market Analysis in Asia-Pacific by Country (2021-2030)
• Table 23: Antiviral Drugs Market Analysis in China (2021-2030)
• Table 24: Antiviral Drugs Market Analysis in Japan (2021-2030)
• Table 25: Antiviral Drugs Market Analysis in India (2021-2030)
• Table 26: Antiviral Drugs Market Analysis in Australia (2021-2030)
• Table 27: Antiviral Drugs Market Analysis in South Korea (2021-2030)
• Table 28: Antiviral Drugs Market Analysis in the Rest of Asia-Pacific (2021-2030)
• Table 29: Antiviral Drugs Market Analysis in the Rest of the World (2021-2030)
• Table 30: Antiviral Drugs Market Analysis in the Rest of the World by Region (2021-2030)
• Table 31: Antiviral Drugs Market Analysis in the Middle East (2021-2030)
• Table 32: Antiviral Drugs Market Analysis in Africa (2021-2030)
• Table 33: Antiviral Drugs Market Analysis in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: COVID-19 Impact Analysis on Antiviral Drugs Market
• Figure 3: Antiviral Drugs Market Analysis in Global (2021-2030)
• Figure 4: Antiviral Drugs Market Analysis in Global by Drug Class (2021-2030)
• Figure 5: Antiviral Drugs Market Analysis in Global by Indication (2021-2030)
• Figure 6: Antiviral Drugs Market Analysis in Global by Distribution Channel (2021-2030)
• Figure 7: Antiviral Drugs Market Analysis in Global by Geography (2021-2030)
• Figure 8: Antiviral Drugs Market Analysis in North America (2021-2030)
• Figure 9: Antiviral Drugs Market Analysis in North America by Country (2021-2030)
• Figure 10: Antiviral Drugs Market Analysis in the US (2021-2030)
• Figure 11: Antiviral Drugs Market Analysis in Canada (2021-2030)
• Figure 12: Antiviral Drugs Market Analysis in Mexico (2021-2030)
• Figure 13: Antiviral Drugs Market Analysis in Europe (2021-2030)
• Figure 14: Antiviral Drugs Market Analysis in Europe by Country (2021-2030)
• Figure 15: Antiviral Drugs Market Analysis in France (2021-2030)
• Figure 16: Antiviral Drugs Market Analysis in Germany (2021-2030)
• Figure 17: Antiviral Drugs Market Analysis in the UK (2021-2030)
• Figure 18: Antiviral Drugs Market Analysis in Italy (2021-2030)
• Figure 19: Antiviral Drugs Market Analysis in Spain (2021-2030)
• Figure 20: Antiviral Drugs Market Analysis in the Rest of Europe (2021-2030)
• Figure 21: Antiviral Drugs Market Analysis in Asia-Pacific (2021-2030)
• Figure 22: Antiviral Drugs Market Analysis in Asia-Pacific by Country (2021-2030)
• Figure 23: Antiviral Drugs Market Analysis in China (2021-2030)
• Figure 24: Antiviral Drugs Market Analysis in Japan (2021-2030)
• Figure 25: Antiviral Drugs Market Analysis in India (2021-2030)
• Figure 26: Antiviral Drugs Market Analysis in Australia (2021-2030)
• Figure 27: Antiviral Drugs Market Analysis in South Korea (2021-2030)
• Figure 28: Antiviral Drugs Market Analysis in the Rest of Asia-Pacific (2021-2030)
• Figure 29: Antiviral Drugs Market Analysis in the Rest of the World (2021-2030)
• Figure 30: Antiviral Drugs Market Analysis in the Rest of the World by Region (2021-2030)
• Figure 31: Antiviral Drugs Market Analysis in the Middle East (2021-2030)
• Figure 32: Antiviral Drugs Market Analysis in Africa (2021-2030)
• Figure 33: Antiviral Drugs Market Analysis in South America (2021-2030)
• Figure 34: Market Drivers
• Figure 35: Market Barriers
• Figure 36: Market Opportunities
• Figure 37: PORTER's Five Force Analysis

Antiviral Drugs Market By Drug Class (Dna Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Neuraminidase Inhibitors, Protease Inhibitors, And Others), By Indication (Hiv Infection, Herpes, Hepatitis, Influenza, And Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, And E-Commerce), and by geography is expected to advance at a respectable CAGR forecast till 2030 owing to the increasing prevalence of various infectious diseases such as influenza, hiv, hepatitis, and others and the increasing initiatives to curb the viral diseases by public and private companies across the globe

The global antiviral drugs market will grow at a CAGR of 3.65% during the forecast period from 2024 to 2030 to reach USD 51,466.21 million by 2030. The antiviral drugs market is observing substantial market growth owing to the increasing prevalence of HIV, hepatitis, Ebola, and other viral diseases across the globe. Further, the growing initiatives for the awareness of viral diseases and the increasing geriatric population base prone to viral diseases will also aid in increasing the demand for antiviral drugs. Additionally, the rising advancements in antiviral drugs such as proteolysis targeting chimera mechanism, targeted covalent inhibitor mechanism, and others to improve the efficacy of the drug will spur the market of antiviral drugs. Similarly, the increasing research & developmental activities along with the surging drug approvals and launches, and the presence of key players in the market, are some of the key factors that will create a requisite for antiviral drugs in the market. Therefore, the market for antiviral drugs is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.

Antiviral Drugs Market Dynamics:

As per the World Health Organization (WHO) 2022, nearly 38.4 million people were living with HIV infection in 2022, globally. The source also stated that nearly 36.7 million were adults (aged 15 and above) and approximately 1.7 million people were children, aged less than 15 years.

The source UNAIDS 2022 report added that nearly 1.5 million people became newly infected with HIV infection, in 2022, globally. The aforesaid source also mentioned that in 2022, 28.7 million people were accessing antiretroviral therapy, globally.

Furthermore, the Joint United Nations Programme on HIV and AIDS also estimated that as of June 2020, 26 million people were accessing antiretroviral therapy, whereas, in 2019, about 25.4 million people were getting antiretroviral therapy. The data suggest that access to anti-viral therapeutic drugs is continuously increasing across the world, which is acting as one of the major factors propelling the market growth. Thus, the increasing prevalence of HIV infection and the increasing awareness regarding the infection will ultimately increase the demand for antiviral drugs used in the treatment of HIV infection.

Additionally, the growing research and developmental activities, expanding product launches and approvals around the world, presence of a robust number of drugs in the pipeline, and strategic activities by the key players to increase the manufacturing and research for the anti-viral drugs will in turn bolster the market of antiviral drugs. For instance, in April 2022, Atriva Therapeutics GmbH, a biopharmaceutical company specifically pioneering the development of host-targeting antiviral therapies received EUR 11.4 million in federal funding. The company has planned to use the funds to advance its drug ATR-002, which is currently in a Phase II clinical study called RESPIRE.

Also, in January 2022, Gilead Sciences, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted expedited approval of a supplemental new drug application (sNDA) for Veklury® (remdesivir) for the treatment of non-hospitalized adult and adolescent patients who are at high risk of progression to severe COVID-19, including hospitalization or death. This approval expands the role of Veklury, which is the antiviral standard of care for the treatment of patients hospitalized with COVID-19.

Furthermore, advances in molecular biology are promoting drug development in tandem with the growing use of nucleoside and nucleotide analogs as first-line antivirals. According to the market's current development pipeline, many small molecule-based anti-viral drugs are expected to receive product approvals in the future, propelling market growth to unprecedented heights during the forecast period.

Therefore, the factors stated above collectively will drive the overall antiviral drugs market during the forecast period from 2024-2030.

However, the emergence of antiviral drug resistance, side effects associated with antiviral drugs, the high cost of the therapy, and the stringent regulatory approval process may prove to be challenging factors for antiviral drug market growth.

The antiviral drugs market was positively impacted during the period of COVID- 19 pandemic as they were used to prevent the spread of the SARS-CoV-2 virus, along with other infectious agents. Although during the initial stage of the lockdown, the market suffered a downfall owing to the strict lockdown restrictions and disruption in manufacturing, and supply chains. However, as the demand for antiviral drugs upsurges the key players in the market accelerated their manufacturing. Many key players indulged in strategic decisions, investments, and research & developmental activities concerning antiviral drugs, leading to an increased demand for antiviral drugs. Moreover, in October 2020, the U.S. Food and Drug Administration approved the antiviral drug Veklury (remdesivir) for use in adult and pediatric patients 12 years of age and older for the treatment of COVID-19 requiring hospitalization. Henceforth, the wide use of antiviral drugs for the prevention of the spread of COVID-19 among the population significantly contributed to the positive growth of the Antiviral drugs market over the forecast period (2022 - 2028).

Antiviral Drugs Market Segment Analysis:

Antiviral Drugs Market by Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Neuraminidase Inhibitors, Protease Inhibitors, and Others), Indication (HIV Infection, Herpes, Hepatitis, Influenza, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and E-Commerce), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the indication segment of the antiviral drugs market, influenza is expected to have a significant revenue share in the year 2023. This was primarily owing to the rising demand and availability of antivirals drugs in the market owing to the increasing prevalence of various viral diseases, expanding launches and strategic investments and other activities relating to antiviral drugs by key players in the market, and wide application and advantages offered by the segment. Lastly, the increasing burden of covid-19 infection across the globe aids in growing the demand for influenza-treating antiviral drugs.

For instance, as per the Centers for Disease Control and Prevention (CDC), from September 28, 2020, to May 22, 2022, in the United States, 1,675 (0.2%) of 818,939 respiratory specimens tested by US clinical laboratories were found positive for an influenza virus.

Also, as per the WHO Virological Surveillance Summary 2022, from week 1, 2022 to week 44, 2022, nearly 54,051 of 418,329 were found positive for an influenza virus in China. The enlarged diagnosis of influenza across various regions across the globe is expected to affect the market optimistically, as more patients will reach out for antiviral therapies after being diagnosed.

Furthermore, surging research and developmental activities, drug launches and approvals, the presence of a robust number of influenza-treating antiviral drugs in the pipeline, and other factors will create a productive opportunity for market growth during the upcoming years. For instance, in November 2022, Seqirus, a global leader in influenza, announced that the U.S. Food and Drug Administration (FDA) has granted supplemental approval of a multi-dose vial (MDV) formulation of AUDENZ(TM) (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted), the first-ever adjuvant, cell-based influenza vaccine designed to help protect individuals six months of age and older against influenza A (H5N1) in the event of a pandemic.

Also, in October 2019, the US Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) of Xofluza (baloxavir marboxil) to treat acute, uncomplicated influenza (flu). The drug is indicated for individuals aged 12 years and above experiencing symptoms for no more than 48 hours and at high risk of flu-related complications.

Therefore, owing to the above-mentioned factors, the demand for influenza drugs upsurges, thereby the category is expected to witness considerable growth eventually contributing to the overall growth of the global antiviral drugs market during the forecast period.

North America is expected to dominate the overall Antiviral Drugs Market:

Among all the regions, North America is expected to dominate the global antiviral drugs in the year 2023 and is expected to do the same during the forecast period from 2024-2030.

This can be ascribed to the increasing demand for antiviral drugs in the region owing to the increasing prevalence of many viral and infectious diseases, the increasing geriatric patient pool suffering from viral diseases, the growing initiatives for the awareness of viral diseases, the launch of new drugs, the presence of key market players in the region, and others are among the key factors that contribute to the growth of the antiviral drugs market in North America.

For instance, according to the latest estimates from the Centers for Disease Control and Prevention (CDC), approximately 34,800 new HIV infections occurred in the United States in 2019. Also, at year-end 2019, an estimated 1.2 million people in the United States aged 13 and older had HIV in the United States. Thus, the increasing prevalence of HIV infection in the United States will increase the demand for many antiviral drugs.

Furthermore, according to the latest study conducted by the U.S. Department of Health & Human Services, approximately 2.4 million people were estimated to be living with hepatitis C in the United States and nearly 850,000 people in the US were estimated to be living with hepatitis B, in 2022.

Additionally, the spread of the pandemic in the region also impacted the market of antiviral drugs.

Moreover, the antiviral drug launches, regulatory approvals, and other activities such as acquisitions, and agreements, in the region will lead to its increased demand in the market. For instance, in August 2020, ViiV Healthcare, the global specialist HIV Company headquartered in the United States, received the US Food and Drug Administration (FDA) approval for its Dovato as a complete regimen for the treatment of HIV-1 infection to replace the current antiretroviral (ARV) regimen in adults who are virologically suppressed.

Additionally, to upsurge the market growth of antiviral drugs, the federal government is providing support funds to pharmaceutical companies to help them to strengthen their clinical development pipelines. For instance, in July 2020, Novavax and Regeneron received USD 2 billion in funding from the US federal government to manufacture drugs and vaccines against COVID-19.

Moreover, the presence of sophisticated healthcare infrastructure and high awareness among end-users such as clinicians and healthcare professionals are estimated to be the key growth drivers. Also, the presence of favorable reimbursement policies is anticipated to further fuel North America's antiviral drugs market during the forecast period (2022 - 2028).

Therefore, the interplay of the aforementioned factors above would provide a conducive growth environment for the North America region in the antiviral drugs market.

Antiviral Drugs Market Key Players:

Some of the key market players operating in the antiviral drugs market include AbbVie Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., Cipla Inc., Lupin., ENTOD INTERNATIONAL, AstraZeneca, Dr. Reddy's Laboratories Ltd., GSK plc., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Sanofi, ViiV Healthcare, Aurobindo Pharma., Sun Pharmaceutical Industries Ltd., Viatris Inc., Boehringer Ingelheim, and others.

Recent Developmental Activities in the Antiviral Drugs Market:

In January 2022, Lupin launched the anti-viral drug Molnupiravir in India under the brand name Molnulup for the treatment of adults suffering from COVID-19 in the country.

In January 2022, ENTOD Pharmaceuticals launched MOLENTOD in India. The product will be available at retail chemists, pharmacy chains, hospitals, and online stores at an affordable price.

In December 2022, the U.S. Food and Drug Administration (FDA) granted an emergency use authorization (EUA) to molnupiravir for use in certain populations where other treatments are not feasible.

In October 2020, Roche announced a partnership with Atea Pharmaceuticals to develop, manufacture, and commercialize Atea's AT-527, an investigational oral antiviral drug for the COVID-19 treatment. This partnership has enhanced the firm's development potential, thus strengthening its market position.

In May 2020, Cipla and Gilead Sciences entered a partnership alliance to develop and commercialize the investigational medicine being used to treat COVID-19-affected patients.

Key Takeaways from the Antiviral Drugs Market Report Study

• Market size analysis for current antiviral drugs market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the antiviral drugs market.
• Top key products/services/ developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global antiviral drugs market.
• Various opportunities available for the other competitor in the antiviral drugs market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030.
• Which are the top-performing regions and countries in the current antiviral drugs market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for antiviral drugs market growth in the coming future?

Target Audience who can be benefited from this Antiviral Drugs Market Report Study

• Antiviral drugs products providers
• Research organizations and consulting companies
• Antiviral drugs -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in antiviral drugs
• Various end users who want to know more about the antiviral drugs market and the latest developments in the antiviral drugs market.

Frequently Asked Questions for the Antiviral Drugs Market:

1. What are antiviral drugs?

Antiviral drugs are a class of medication used for treating viral infections. Most antivirals target specific viruses, while a broad-spectrum antiviral is effective against a wide range of viruses.

2. What is the global market for antiviral drugs?

The global antiviral drugs market will grow at a CAGR of 3.65% during the forecast period from 2024 to 2030 to reach USD 51,466.21 million by 2030.

3. What are the drivers for the global antiviral drugs market?

The antiviral drugs market is witnessing positive market growth owing to the factors such as the growing prevalence of various infectious diseases such as HIV, herpes, influenza, and others, growing initiatives for the awareness of infectious diseases, increasing geriatric population base prone to various infectious diseases such as influenza, hepatitis, rising strategic steps by the key players for the development and manufacturing of antiviral drugs, increasing new drug launches and approvals, presence of key players in the market, and others will create an exigency for the antiviral drugs market.

4. Who are the key players operating in the global antiviral drugs market?

Some of the key market players operating in the Antiviral drugs market include AbbVie Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., Cipla Inc., Lupin., ENTOD INTERNATIONAL, AstraZeneca, Dr. Reddy's Laboratories Ltd., GSK plc., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Sanofi, ViiV Healthcare, Aurobindo Pharma., Sun Pharmaceutical Industries Ltd., Viatris Inc., Boehringer Ingelheim, and others.

5. Which region has the highest share of the antiviral drugs market?

Among all the regions, North America is estimated to hold a significant revenue share in the global antiviral drugs market. This can be ascribed to the increasing demand for antiviral drugs among the patients in the region owing to the increasing prevalence of HIV, hepatitis, covid-19, and other viral diseases. Further, the growing initiatives for the awareness of viral diseases, the increasing geriatric population base prone to viral diseases, and the presence of key domicile players in the region are the reasons which act as a supportive factor for the North American antiviral drugs market growth.

Table of Contents

1.Antiviral Drugs Market Report Introduction

2. Antiviral Drugs Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Regulatory Analysis

4. Antiviral Drugs Market Key Factors Analysis

• 4.1. Antiviral Drugs Market Drivers
  • 4.1.1. Growing prevalence of various infectious diseases such as HIV, Herpes, Influenza, and others
  • 4.1.2. Growing initiatives for the awareness of infectious diseases
  • 4.1.3. Increasing geriatric population base prone to various infectious diseases such as Influenza, Hepatitis
  • 4.1.4. Rising strategic steps by the key players for the development and manufacturing of antiviral drugs
• 4.2. Antiviral Drugs Market Restraints and Challenges
  • 4.2.1. The emergence of antiviral drugs resistance
  • 4.2.2. Side effects associated with the antiviral drug
• 4.3. Antiviral Drugs Market Opportunities
  • 4.3.1. Increasing approval and expected commercialization of novel medicines for viral infections

5. Antiviral Drugs Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Antiviral Drugs Market

7. Antiviral Drugs Market Layout

• 7.1. By Drug Class
  • 7.1.1. DNA Polymerase Inhibitors
  • 7.1.2. Reverse Transcriptase Inhibitors
  • 7.1.3. Neuraminidase Inhibitors
  • 7.1.4. Protease Inhibitors
  • 7.1.5. Others
• 7.2. By Indication
  • 7.2.1. HIV Infection
  • 7.2.2. Herpes
  • 7.2.3. Hepatitis
  • 7.2.4. Influenza
  • 7.2.5. Others
• 7.3. By Distribution Channel
  • 7.3.1. Hospital Pharmacy
  • 7.3.2. Retail Pharmacy
  • 7.3.3. E-commerce
• 7.4. By Geography
  • 7.4.1. North America
    • 7.4.1.1. United States Antiviral Drugs Market in USD million (2021-2030)
    • 7.4.1.2. Canada Antiviral Drugs Market in USD million (2021-2030)
    • 7.4.1.3. Mexico Antiviral Drugs Market in USD million (2021-2030)
  • 7.4.2. Europe
    • 7.4.2.1. France Antiviral Drugs Market in USD million (2021-2030)
    • 7.4.2.2. Germany Antiviral Drugs Market in USD million (2021-2030)
    • 7.4.2.3. United Kingdom Antiviral Drugs Market in USD million (2021-2030)
    • 7.4.2.4. Italy Antiviral Drugs Market in USD million (2021-2030)
    • 7.4.2.5. Spain Antiviral Drugs Market in USD million (2021-2030)
    • 7.4.2.6. Rest of Europe Antiviral Drugs Market in USD million (2021-2030)
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. China Antiviral Drugs Market in USD million (2021-2030)
    • 7.4.3.2. Japan Antiviral Drugs Market in USD million (2021-2030)
    • 7.4.3.3. India Antiviral Drugs Market in USD million (2021-2030)
    • 7.4.3.4. Australia Antiviral Drugs Market in USD million (2021-2030)
    • 7.4.3.5. South Korea Antiviral Drugs Market in USD million (2021-2030)
    • 7.4.3.6. Rest of Asia Pacific Antiviral Drugs Market in USD million (2021-2030)
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. Middle East Antiviral Drugs Market in USD million (2021-2030)
    • 7.4.4.2. Africa Antiviral Drugs Market in USD million (2021-2030)
    • 7.4.4.3. South America Antiviral Drugs Market in USD million (2021-2030)

8. Antiviral Drugs Market Company and Product Profiles

• 8.1. AbbVie Inc.
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4 Product Listing
  • 8.1.5. Entropy
• 8.2. Bristol-Myers Squibb Company
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4 Product Listing
  • 8.2.5. Entropy
• 8.3. Gilead Sciences, Inc.
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4 Product Listing
  • 8.3.5. Entropy
• 8.4. F. Hoffmann-La Roche Ltd
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4 Product Listing
  • 8.4.5. Entropy
• 8.5. Pfizer Inc.
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4 Product Listing
  • 8.5.5. Entropy
• 8.6. Cipla Inc.
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4 Product Listing
  • 8.6.5. Entropy
• 8.7. Lupin.
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4 Product Listing
  • 8.7.5. Entropy
• 8.8. ENTOD INTERNATIONAL
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4 Product Listing
  • 8.8.5. Entropy
• 8.9. AstraZeneca
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4 Product Listing
  • 8.9.5. Entropy
• 8.10. Dr. Reddy's Laboratories Ltd.
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4 Product Listing
  • 8.10.5. Entropy
• 8.11. GSK plc.
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4 Product Listing
  • 8.11.5. Entropy
• 8.12. Johnson & Johnson
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4 Product Listing
  • 8.12.5. Entropy
• 8.13. Merck & Co., Inc.
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4 Product Listing
  • 8.13.5. Entropy
• 8.14. Novartis AG
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4 Product Listing
  • 8.14.5. Entropy
• 8.15. Sanofi
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4 Product Listing
  • 8.15.5. Entropy
• 8.16. ViiV Healthcare
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4 Product Listing
  • 8.16.5. Entropy
• 8.17. Aurobindo Pharma.
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4 Product Listing
  • 8.17.5. Entropy
• 8.18. Sun Pharmaceutical Industries Ltd.
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4 Product Listing
  • 8.18.5. Entropy
• 8.19. Viatris Inc.
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4 Product Listing
  • 8.19.5. Entropy
• 8.20. Boehringer Ingelheim
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4 Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us